4-Amino-2-Trifluoromethyl-Phenyl Retinate induced leukemia cell differentiation by decreasing eIF6

Wang, Ke; Zhu, Chuan‐Jun; Li, Ge; Li, Yue; Feng, Yongzeng; Ruan, Jingjing; Zhu, Fei; Meng, Yao; Zhou, Ren‐Peng; Chen, Feihu

doi:10.1016/j.bbrc.2018.07.153

Cited by 6 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ATPR, a derivative of ATRA, has been confirmed to repress proliferation and induce differentiation of various cancer cells effectively including breast, ovarian, esophageal, hepatocellular and gastric cancer [1]. Our previous studies have demonstrated that ATPR can inhibit proliferation, induce differentiation and apoptosis of NB4 [10], K562 [17,18] and SKM-1 [19] in vitro. In the present study, we explored that the therapeutic effect of ATPR suppresses APL xenograft mouse model via the regulation of PI3K/AKT, ERK and Notch signaling pathway.…”

Section: Discussionmentioning

confidence: 99%

A novel retinoic acid analog, 4-Amino-2-Trifluoromethyl-Phenyl Retinate (ATPR) triggers differentiation and is effective in the treatment of Acute Promyelocytic Leukemia

Bao

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Acute promyelocytic leukemia (APL), form RARα fusion genes and proteins is one of the most prevalent forms of leukemia. 4-Amino-2-Trifluoromethyl-Phenyl Retinate (ATPR), a derivative of all-trans-retinoic acid (ATRA), is of potent functions in the induce of cell differentiation, growth arrest, and apoptosis. Nowadays, we aimed to investigate the therapeutic effect of ATPR on this APL pathological model, and whether the mechanism involves PI3K/AKT, ERK and Notch signaling. We established a human xenograft mouse model using NB4 cells and found that ATPR significantly increased the protein concentration in the CD11b and suppressed the PI3K/AKT signaling and activated the ERK and Notch signaling in tumor tissue. Collectively, these data suggest that ATPR shows antileukemic effects by regulating PI3K/AKT, ERK and Notch signaling.

show abstract

Section: Discussionmentioning

confidence: 99%

A novel retinoic acid analog, 4-Amino-2-Trifluoromethyl-Phenyl Retinate (ATPR) triggers differentiation and is effective in the treatment of Acute Promyelocytic Leukemia

Bao

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…The classic translation process in eukaryotes is mainly divided into four steps: initiation, elongation, termination, and the release of the free polypeptide [9]. As studied in our previous research, several eukaryotic translation initiation factors (eIFs) were implicated in ATRA-induced leukemia cell development [10,11]. The 5 m7GpppN cap (cap)-dependent translation initiation is the classic translation initiation pattern in eukaryotes, accounting for most protein synthesis under normal growth conditions, and was dysregulated in many solid tumors and leukemia [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

The Translational Landscape Revealed the Sequential Treatment Containing ATRA plus PI3K/AKT Inhibitors as an Efficient Strategy for AML Therapy

Wang

Deng

et al. 2022

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

The present study aimed to better understand the possibility of utilizing all-trans retinoic acids (ATRA) in acute myeloid leukemia (AML). We found that ATRA significantly suppressed global translation and protein synthesis in AML cells. The efficacy of ATRA in treating AML required its translational regulatory functions, as shown by the fact that the decrease in the universal eukaryotic initiation factor 4E (eIF4E) was essential to maintain the induction of cell growth arrest and differentiation by ATRA. By establishing a specific translational landscape, we suggested that transcripts with simple 5′UTR gained a translational advantage in AML cells during ATRA stress. Based on that, the genes translationally regulated by ATRA were mainly enriched in phosphatidylinositol-3-kinase/Akt (PI3K/AKT) signaling; we subsequently revealed that PI3K/AKT activation was required for ATRA to effectively induce AML cell differentiation. However, PI3K/AKT has been reported to promote the stemness of AML cells. As such, we further suggested that sequential treatment including ATRA and PI3K/AKT inhibitor induced robust apoptosis, extremely inhibited the clonality of AML cells, and suppressed the FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-driven transformation of CD34+ hematopoietic stem/progenitor cells. Future clinical studies are warranted to further support the clinical application of the sequential strategy for the effective treatment of AML.

show abstract

4-Amino-2-trifluoromethyl-phenyl retinate induced differentiation of human myelodysplastic syndromes SKM-1 cell lines by up-regulating DDX23

Wang

Song

et al. 2020

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

4-Amino-2-Trifluoromethyl-Phenyl Retinate induced leukemia cell differentiation by decreasing eIF6

Cited by 6 publications

References 25 publications

A novel retinoic acid analog, 4-Amino-2-Trifluoromethyl-Phenyl Retinate (ATPR) triggers differentiation and is effective in the treatment of Acute Promyelocytic Leukemia

A novel retinoic acid analog, 4-Amino-2-Trifluoromethyl-Phenyl Retinate (ATPR) triggers differentiation and is effective in the treatment of Acute Promyelocytic Leukemia

The Translational Landscape Revealed the Sequential Treatment Containing ATRA plus PI3K/AKT Inhibitors as an Efficient Strategy for AML Therapy

4-Amino-2-trifluoromethyl-phenyl retinate induced differentiation of human myelodysplastic syndromes SKM-1 cell lines by up-regulating DDX23

Contact Info

Product

Resources

About